Pub Date : 2022-03-01DOI: 10.1097/CP9.0000000000000009
Yu-Juan Yu, Y. Tse, Siyun Yu, L. Lam, K. Li, Yan Chen, Mei-Zhen Wu, Q. Ren, S. Yu, P. Wong, H. Tse, K. Yiu
Abstract Background: Patients who undergo concomitant aortic and mitral double valve replacement (DVR) have poor postoperative clinical outcomes. The modified Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI) score and the modified Model for End-Stage Liver Disease score with albumin replacing international normalized ratio (MELD-albumin) score have been reported as predictors of adverse events in hepato-cardiac diseases. The objective of this study was to assess the clinical prognostic value of the two modified Model for End-Stage Liver Disease (MELD) scores in patients undergoing DVR. Methods: A total of 210 patients undergoing DVR were evaluated. Baseline clinical and laboratory parameters were recorded, and EuroSCORE II was calculated for each patient. The outcome of interest was the composite of heart failure hospitalization and cardiovascular mortality. Results: Patients undergoing DVR had a high prevalence of hepato-renal dysfunction. During a median follow-up of 71 months, the MELD-XI and MELD-Albumin scores independently predicted adverse outcomes (hazard ratio [95% confidence interval] = 1.09 [1.03–1.16] and 1.11 [1.06–1.16], P < 0.01, respectively). Kaplan–Meier analysis demonstrated that high MELD-XI and MELD-Albumin scores were associated with an increased risk of adverse events. MELD-Albumin provided incremental prognostic value to clinical parameters and EuroSCORE II (net reclassification index [NRI] = 0.34; P < 0.01). Conclusions: Both the MELD-XI score and MELD-Albumin score can provide useful information to predict adverse outcomes in patients undergoing DVR. The present study supports the monitoring of modified MELD scores to improve preoperative risk stratification for these patients.
{"title":"Prognostic value of MELD-XI and MELD-Albumin scores in double valve replacement","authors":"Yu-Juan Yu, Y. Tse, Siyun Yu, L. Lam, K. Li, Yan Chen, Mei-Zhen Wu, Q. Ren, S. Yu, P. Wong, H. Tse, K. Yiu","doi":"10.1097/CP9.0000000000000009","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000009","url":null,"abstract":"Abstract Background: Patients who undergo concomitant aortic and mitral double valve replacement (DVR) have poor postoperative clinical outcomes. The modified Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI) score and the modified Model for End-Stage Liver Disease score with albumin replacing international normalized ratio (MELD-albumin) score have been reported as predictors of adverse events in hepato-cardiac diseases. The objective of this study was to assess the clinical prognostic value of the two modified Model for End-Stage Liver Disease (MELD) scores in patients undergoing DVR. Methods: A total of 210 patients undergoing DVR were evaluated. Baseline clinical and laboratory parameters were recorded, and EuroSCORE II was calculated for each patient. The outcome of interest was the composite of heart failure hospitalization and cardiovascular mortality. Results: Patients undergoing DVR had a high prevalence of hepato-renal dysfunction. During a median follow-up of 71 months, the MELD-XI and MELD-Albumin scores independently predicted adverse outcomes (hazard ratio [95% confidence interval] = 1.09 [1.03–1.16] and 1.11 [1.06–1.16], P < 0.01, respectively). Kaplan–Meier analysis demonstrated that high MELD-XI and MELD-Albumin scores were associated with an increased risk of adverse events. MELD-Albumin provided incremental prognostic value to clinical parameters and EuroSCORE II (net reclassification index [NRI] = 0.34; P < 0.01). Conclusions: Both the MELD-XI score and MELD-Albumin score can provide useful information to predict adverse outcomes in patients undergoing DVR. The present study supports the monitoring of modified MELD scores to improve preoperative risk stratification for these patients.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"39 - 47"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43026756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1097/CP9.0000000000000004
B. He, Panyang Xu, Qi Zhou, J. Xu, Lu Cai
Abstract Background: Previous studies suggested higher serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) level with older age and in women, but the reference intervals (RIs) recommended by assay manufacturers do not fully recognize such pattern. Aims: In this study, we aimed to establish a set of age- and sex-specific RIs for serum NT-proBNP in healthy adults from Northeast China. Methods: Healthy adult subjects (20 to ≤95 years old) were recruited from the physical examination center at a teaching hospital during a period from March 2020 to July 2020. Serum NT-proBNP concentration was measured using the VITROS 5600 Integrated System with a chemiluminescence method. RIs were calculated based on the EP28-A3c guidelines by the Clinical and Laboratory Standards Institute. A generalized linear model was performed to factors that were associated with NT-proBNP level. Results: The final analysis included 2,183 subjects (1,074 men and 1,109 women, mean age 54.2 ± 19.5 years). Serum NT-proBNP level increased with advancing age (20 to <50, 50 to <60, 60 to <75 and ≥75 years), and was significantly higher in women than in men with the exception of the ≥75 age group. Higher NT-proBNP level was associated with the female sex, older age, lower body mass index, higher urea nitrogen, higher creatinine, lower uric acid, and lower triglyceride (P < 0.05 for all). The strongest association was with the female sex, followed by age. Conclusions: Serum NT-proBNP level must be interpreted with consideration of sex and age. Higher NT-proBNP is associated with the female sex and older age.
{"title":"Serum N-terminal-pro-B-type natriuretic peptide is dependent on age and sex: a cross-sectional analysis in healthy adults from Northeast China","authors":"B. He, Panyang Xu, Qi Zhou, J. Xu, Lu Cai","doi":"10.1097/CP9.0000000000000004","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000004","url":null,"abstract":"Abstract Background: Previous studies suggested higher serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) level with older age and in women, but the reference intervals (RIs) recommended by assay manufacturers do not fully recognize such pattern. Aims: In this study, we aimed to establish a set of age- and sex-specific RIs for serum NT-proBNP in healthy adults from Northeast China. Methods: Healthy adult subjects (20 to ≤95 years old) were recruited from the physical examination center at a teaching hospital during a period from March 2020 to July 2020. Serum NT-proBNP concentration was measured using the VITROS 5600 Integrated System with a chemiluminescence method. RIs were calculated based on the EP28-A3c guidelines by the Clinical and Laboratory Standards Institute. A generalized linear model was performed to factors that were associated with NT-proBNP level. Results: The final analysis included 2,183 subjects (1,074 men and 1,109 women, mean age 54.2 ± 19.5 years). Serum NT-proBNP level increased with advancing age (20 to <50, 50 to <60, 60 to <75 and ≥75 years), and was significantly higher in women than in men with the exception of the ≥75 age group. Higher NT-proBNP level was associated with the female sex, older age, lower body mass index, higher urea nitrogen, higher creatinine, lower uric acid, and lower triglyceride (P < 0.05 for all). The strongest association was with the female sex, followed by age. Conclusions: Serum NT-proBNP level must be interpreted with consideration of sex and age. Higher NT-proBNP is associated with the female sex and older age.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"48 - 55"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47379031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1097/CP9.0000000000000008
Shidi Hu, Ji'e Yang, Feng Zhang
Abstract Primary percutaneous coronary intervention is the current standard treatment for myocardial infarction, but is associated with ischemia/reperfusion injury for which inflammation is an important part. This review summaries the recent findings in the study of pro- and anti-inflammatory signaling pathways (eg, TLR4/Myd88/NF-κB, MAPKs/NF-κB, NLRP3 inflammasome, JAK2/STAT3, and Nrf2/HO-1) in myocardial ischemia/reperfusion injury, as well as relevant drug development efforts. Despite of the vast body of literature, no concrete advances have been made in translating the new knowledge into clinical practice, but we do anticipate major breakthroughs in the foreseeable future.
{"title":"Signaling pathways of inflammation in myocardial ischemia/reperfusion injury","authors":"Shidi Hu, Ji'e Yang, Feng Zhang","doi":"10.1097/CP9.0000000000000008","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000008","url":null,"abstract":"Abstract Primary percutaneous coronary intervention is the current standard treatment for myocardial infarction, but is associated with ischemia/reperfusion injury for which inflammation is an important part. This review summaries the recent findings in the study of pro- and anti-inflammatory signaling pathways (eg, TLR4/Myd88/NF-κB, MAPKs/NF-κB, NLRP3 inflammasome, JAK2/STAT3, and Nrf2/HO-1) in myocardial ischemia/reperfusion injury, as well as relevant drug development efforts. Despite of the vast body of literature, no concrete advances have been made in translating the new knowledge into clinical practice, but we do anticipate major breakthroughs in the foreseeable future.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"29 - 38"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44708546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1097/cp9.0000000000000001
Magnus Bäck, M. Hashem, A. Giani, S. Pawelzik, A. Franco-Cereceda
{"title":"Calcific aortic valve stenosis and COVID-19: clinical management, valvular damage, and pathophysiological mechanisms","authors":"Magnus Bäck, M. Hashem, A. Giani, S. Pawelzik, A. Franco-Cereceda","doi":"10.1097/cp9.0000000000000001","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000001","url":null,"abstract":"","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45433050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.4103/2470-7511.334396
W. Pan, Nan-Chao Hong, J. Ge, Da-Xin Zhou
Prognosis in subjects with coronary artery fistula (CAF) is highly variable. CAF may remain asymptomatic throughout the entire lifetime in some; however, in others, CAF may become hemodynamically significant and complications ensue. CAF closure, either surgically or via a transcatheter approach, eliminates the underlying anatomical anomaly but is associated with a variety of complications, including but not limited to coronary thrombosis and even full-blown myocardial infarction. In this review, we summarize the evidence that argued for versus against CAF closure and attempt to provide a balanced view of the benefits versus harm of CAF closure in patients with different types of CAF.
{"title":"Coronary artery fistula: To close or not close, that is the question","authors":"W. Pan, Nan-Chao Hong, J. Ge, Da-Xin Zhou","doi":"10.4103/2470-7511.334396","DOIUrl":"https://doi.org/10.4103/2470-7511.334396","url":null,"abstract":"Prognosis in subjects with coronary artery fistula (CAF) is highly variable. CAF may remain asymptomatic throughout the entire lifetime in some; however, in others, CAF may become hemodynamically significant and complications ensue. CAF closure, either surgically or via a transcatheter approach, eliminates the underlying anatomical anomaly but is associated with a variety of complications, including but not limited to coronary thrombosis and even full-blown myocardial infarction. In this review, we summarize the evidence that argued for versus against CAF closure and attempt to provide a balanced view of the benefits versus harm of CAF closure in patients with different types of CAF.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"6 1","pages":"256 - 263"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45288638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.4103/2470-7511.334401
Rachel Parise, S. Ramesh, Manoj Govindarajulu, Amir Ajoolabady, Timothy Moore, M. Dhanasekaran
Viral infections persist globally, among all ages, gender, and ethnicity. Of particular importance is COVID-19, associated with asymptomatic to severe symptoms, including complications/mortality. Cardiovascular disease (CVD) involves heart and blood vessel disorders including coronary heart disease, cerebrovascular disease, peripheral artery disease, thrombosis, and more. CVD associated with severe COVID-19 includes heart failure, coronary artery disease, cardiomyopathy, hypertension, and cerebrovascular disease/stroke. Data were acquired from PubMed, Google Scholar, Centers for Disease Prevention and Control, and Lexi-Comp using the search terms “COVID-19 and cardiovascular pathology;” “COVID-19 induced CVD;” “Viral infection induced CVD;” and “Viral infection induced heart damage.” COVID-19-induced CVD mechanisms include direct viral entry, inflammation, cytokine storm, hypoxia, interferon-mediated immune response, plaque destabilization, stress, and drug-induced causes. Other viral pathologies causing CVD include atherosclerosis, inflammation, cytokine storm, and plaque destabilization. Individual parameters, such as old age, males, and higher body mass index (BMI), are more likely to experience viral-associated complications, possibly explained by patient risk factors or comorbidities. Populations at higher risk include older males with an elevated BMI. Viral mechanisms associated with CVD are similar but differ in disease severity, potentially explained by diverse cytokine profiles where COVID-19 activates different types at higher quantities.
{"title":"COVID-19-induced cardiovascular damage differs from other prevalent viruses","authors":"Rachel Parise, S. Ramesh, Manoj Govindarajulu, Amir Ajoolabady, Timothy Moore, M. Dhanasekaran","doi":"10.4103/2470-7511.334401","DOIUrl":"https://doi.org/10.4103/2470-7511.334401","url":null,"abstract":"Viral infections persist globally, among all ages, gender, and ethnicity. Of particular importance is COVID-19, associated with asymptomatic to severe symptoms, including complications/mortality. Cardiovascular disease (CVD) involves heart and blood vessel disorders including coronary heart disease, cerebrovascular disease, peripheral artery disease, thrombosis, and more. CVD associated with severe COVID-19 includes heart failure, coronary artery disease, cardiomyopathy, hypertension, and cerebrovascular disease/stroke. Data were acquired from PubMed, Google Scholar, Centers for Disease Prevention and Control, and Lexi-Comp using the search terms “COVID-19 and cardiovascular pathology;” “COVID-19 induced CVD;” “Viral infection induced CVD;” and “Viral infection induced heart damage.” COVID-19-induced CVD mechanisms include direct viral entry, inflammation, cytokine storm, hypoxia, interferon-mediated immune response, plaque destabilization, stress, and drug-induced causes. Other viral pathologies causing CVD include atherosclerosis, inflammation, cytokine storm, and plaque destabilization. Individual parameters, such as old age, males, and higher body mass index (BMI), are more likely to experience viral-associated complications, possibly explained by patient risk factors or comorbidities. Populations at higher risk include older males with an elevated BMI. Viral mechanisms associated with CVD are similar but differ in disease severity, potentially explained by diverse cytokine profiles where COVID-19 activates different types at higher quantities.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"6 1","pages":"231 - 245"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42766914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Myocardial ischemia and reperfusion (I/R) lead to an inflammatory response that causes cardiac injury and remodeling. However, increasing evidence suggests this is an over-simplified view. Several proinflammatory cytokines, including tumor necrosis factor-α, interleukin-1α, interleukin-6, macrophage migration inhibitory factor and D-dopachrome tautomerase have been shown to improve cell survival and compensate energy deprivation during I/R. This review summarizes the recent findings that support protective role of proinflammatory cytokines against cardiac injury during acute I/R, as well as therapeutic ramifications of these findings.
{"title":"Cardiac protective effects of proinflammatory cytokines during ischemia-reperfusion","authors":"Li-Sha Li, Hong Wu, Shu-Xia Wang, Sui-xin Liu, Le-Qing Lin, Da-Ke Qi","doi":"10.4103/2470-7511.334402","DOIUrl":"https://doi.org/10.4103/2470-7511.334402","url":null,"abstract":"Myocardial ischemia and reperfusion (I/R) lead to an inflammatory response that causes cardiac injury and remodeling. However, increasing evidence suggests this is an over-simplified view. Several proinflammatory cytokines, including tumor necrosis factor-α, interleukin-1α, interleukin-6, macrophage migration inhibitory factor and D-dopachrome tautomerase have been shown to improve cell survival and compensate energy deprivation during I/R. This review summarizes the recent findings that support protective role of proinflammatory cytokines against cardiac injury during acute I/R, as well as therapeutic ramifications of these findings.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"6 1","pages":"246 - 255"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43302434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.4103/2470-7511.334403
Donghui Zhao, Sidney Smith Jr
Acute coronary syndrome (ACS) is a severe clinical manifestation of ischemic heart disease with a high risk of death. The quality of care provided by the health system and medical providers to patients with ACS in daily clinical practice determines the likelihood of desired health outcomes or prognosis. This review provides an overview of several key issues in the quality of care for ACS, including how to measure the quality of care for ACS and the main strategies to improve the quality of care for ACS patients in both the acute and chronic phases. Efforts to improve the quality of care for ACS through specific programs in Western countries and in China are also described.
{"title":"Quality of Care for Patients with Acute Coronary Syndrome","authors":"Donghui Zhao, Sidney Smith Jr","doi":"10.4103/2470-7511.334403","DOIUrl":"https://doi.org/10.4103/2470-7511.334403","url":null,"abstract":"Acute coronary syndrome (ACS) is a severe clinical manifestation of ischemic heart disease with a high risk of death. The quality of care provided by the health system and medical providers to patients with ACS in daily clinical practice determines the likelihood of desired health outcomes or prognosis. This review provides an overview of several key issues in the quality of care for ACS, including how to measure the quality of care for ACS and the main strategies to improve the quality of care for ACS patients in both the acute and chronic phases. Efforts to improve the quality of care for ACS through specific programs in Western countries and in China are also described.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"6 1","pages":"202 - 209"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46928291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.4103/2470-7511.334399
D. Yan, Yongming Zhang, Yu-hua Ji, Tao Wang, Xiao-Xing Xiong, Heng Zhao
Backgrounds: Whether there are distinctive macrophage functional phenotypes of M1 versus M2 has been debated. We re-examined them by studying M1/M2 gene and protein expressions in cultured BV2 microglial cells and their effects on stroke outcomes in vivo. Methods: BV2 microglia cells were cultured and polarized with lipopolysaccharide (LPS) and interleukin-4 (IL-4) to produce M (LPS) and M (IL-4) phenotypes, which were originally defined as M1 and M2 phenotypes, respectively. Typical M1 and M2 gene or protein expression patterns were analyzed in M (LPS) and M (IL-4) phenotypes and their distinctive effects on stroke outcomes were compared. Results: M (LPS) and M (IL-4) had distinctive morphologies. M (IL-4) had significantly higher gene expressions of the typical M2 markers and other anti-inflammatory genes, while M (LPS) had higher gene expression of typical M1 markers and other pro-inflammatory genes. Nevertheless, M2 gene expressions were also enhanced in M (LPS), and M1 gene expressions were increased in M (IL-4), although with relatively lower levels. Adoptive transfer of M (IL-4) reduced infarction and improved neurological scores, while M (LPS) macrophages generated the opposite effect. Fluorescence activated cell sorting (FACS) and confocal studies suggest that M (IL-4) inhibited, while M (LPS) promoted the infiltration of monocyte-derived macrophages and iNOS-positive cells. Conclusions: M (LPS) and M (IL-4) from cultured BV2 cells indeed are distinctive functional phenotypes, but it is inaccurate to simply classify them into M1 and M2 phenotypes based on a few typical gene and protein markers.
{"title":"Re-visit the concept of M1 versus M2 phenotypes of BV2 microglia and test their effects on stroke outcome in mice","authors":"D. Yan, Yongming Zhang, Yu-hua Ji, Tao Wang, Xiao-Xing Xiong, Heng Zhao","doi":"10.4103/2470-7511.334399","DOIUrl":"https://doi.org/10.4103/2470-7511.334399","url":null,"abstract":"Backgrounds: Whether there are distinctive macrophage functional phenotypes of M1 versus M2 has been debated. We re-examined them by studying M1/M2 gene and protein expressions in cultured BV2 microglial cells and their effects on stroke outcomes in vivo. Methods: BV2 microglia cells were cultured and polarized with lipopolysaccharide (LPS) and interleukin-4 (IL-4) to produce M (LPS) and M (IL-4) phenotypes, which were originally defined as M1 and M2 phenotypes, respectively. Typical M1 and M2 gene or protein expression patterns were analyzed in M (LPS) and M (IL-4) phenotypes and their distinctive effects on stroke outcomes were compared. Results: M (LPS) and M (IL-4) had distinctive morphologies. M (IL-4) had significantly higher gene expressions of the typical M2 markers and other anti-inflammatory genes, while M (LPS) had higher gene expression of typical M1 markers and other pro-inflammatory genes. Nevertheless, M2 gene expressions were also enhanced in M (LPS), and M1 gene expressions were increased in M (IL-4), although with relatively lower levels. Adoptive transfer of M (IL-4) reduced infarction and improved neurological scores, while M (LPS) macrophages generated the opposite effect. Fluorescence activated cell sorting (FACS) and confocal studies suggest that M (IL-4) inhibited, while M (LPS) promoted the infiltration of monocyte-derived macrophages and iNOS-positive cells. Conclusions: M (LPS) and M (IL-4) from cultured BV2 cells indeed are distinctive functional phenotypes, but it is inaccurate to simply classify them into M1 and M2 phenotypes based on a few typical gene and protein markers.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"6 1","pages":"264 - 273"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47752503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：